NICE unlicensed medicine evidence summary: Oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia

Source: NICE Area: Evidence > Drug Specific Reviews These evidence summaries review the published data for selected unlicensed or off-label medicines that are considered to be of significance to the NHS, where there are no clinically appropriate licensed alternatives. The summaries provide information for clinicians and patients to inform their decision-making and support the construction and updating of local formularies.   The latest summary addresses the use of oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia, which the BNF states is a suitable preparation for this indication when used in people who have already been treated for hypomagnesaemia. Oral magnesium glycerophosphate does not have UK marketing authorisation for this or any other indication, and therefore it is an unlicensed medicine in the UK.   No relevant controlled clinical trials of oral magnesium glycerophosphate in patients who have previously been treated with an intravenous infusion of magnesium were identified. The ...
Source: NeLM - Drug Specific Reviews - Category: Drugs & Pharmacology Source Type: news